<DOC>
	<DOCNO>NCT01825824</DOCNO>
	<brief_summary>The standard treatment hepatocellular carcinoma ( HCC ) surgery , , hepatic resection liver transplantation , le 20 % HCC patient suitable surgery . In remain patient inoperable advanced HCC , trans-arterial chemo-embolization ( TACE ) widely use TACE alone rarely produce complete response commonly develop recurrence . Recently several small study report high tumor response local control rate stereotactic ablative radiotherapy ( SABR ) alone TACE inoperable HCC . This study evaluate SABR effect 60 Gy 3 fractionation HCC size ≤ 5 cm 3 cm apart gastrointestinal tract .</brief_summary>
	<brief_title>Stereotactic Ablative Radiotherapy Hepatocellular Carcinoma ≤ 5 cm</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Male female patient ≥ 20 year age Initially diagnose recurrent hepatocellular carcinoma ( HCC ) Unresectable HCC Cirrhotic status Child Pugh class A B7 Eastern Cooperative Oncology Group performance status 0 1 single sum multiple tumor ≤ 5 cm HCC 3 cm apart gastrointestinal tract The volume uninvolved must least 700 ml Incomplete response transarterial chemoembolization 15 A single lesion multiple lesion include portal vein tumor thrombosis include radiation field one consecutive session stereotactic body radiation therapy ( SBRT ) No evidence uncontrolled lesion site No evidence complication liver cirrhosis No evidence uncontrolled intercurrent illness Patient guardian must able provide verbal write informed consent Patient previous history abdominal radiation Direct invasion esophagus , stomach colon HCC</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Stereotactic ablative radiotherapy</keyword>
	<keyword>Stereotactic body radiotherapy</keyword>
</DOC>